Bedford Laboratories, a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 1992, the company has established itself as a leader in the development and manufacturing of high-quality injectable pharmaceuticals. With a focus on sterile injectable products, Bedford Laboratories serves a diverse range of healthcare providers across North America and beyond. The company is renowned for its commitment to quality and innovation, offering a comprehensive portfolio that includes generic and specialty injectable medications. Notable achievements include securing FDA approvals for numerous products, which has solidified its market position. Bedford Laboratories continues to prioritise patient safety and efficacy, making it a trusted name in the pharmaceutical landscape.
How does Bedford Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Bedford Laboratories's score of 28 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bedford Laboratories, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Hikma Pharmaceuticals PLC, which may influence its climate commitments and reporting practices. While Bedford Laboratories has not established its own reduction targets or climate pledges, it is important to note that it inherits emissions data and sustainability initiatives from its parent company, Hikma Pharmaceuticals PLC. This relationship suggests that Bedford Laboratories may align its environmental strategies with those of Hikma, which is actively engaged in climate action and sustainability efforts. As of now, Bedford Laboratories has not disclosed any specific reduction initiatives or targets, nor has it committed to the Science Based Targets initiative (SBTi). The lack of detailed emissions data and reduction commitments highlights an opportunity for Bedford Laboratories to enhance its climate strategy and transparency in the future.
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 16,817,000 | - | - | 00,000,000 | 00,000,000 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 
| Scope 2 | 49,779,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 
| Scope 3 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 
Bedford Laboratories's Scope 3 emissions, which decreased by 95% last year and decreased by approximately 94% since 2021, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 26% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 1599% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bedford Laboratories has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.